Figure Legends
Figure 1. Receiver operating curve (ROC) curve analysis using the neutrophil to lymphocyte ratio (NLR), the platelet-lymphocyte ratio (PLR) and ∆PMMA to differentiate between patients with and without hyperprogressive disease. The diagnostic accuracy of biomarkers was determined by obtaining the largest possible area under the curve (AUC) in ROC analysis A. NLR2 AUC=0.85; B. PLR2 AUC=0.79;C. ∆PMMA AUC=0.89.
Figure 2. Kaplan-Meier estimates of overall survival (OS) in hyperprogressors (HPs), pseudoprogressors (PPs), progressors (Ps), nonprogressors (NPs) and patients with sarcopenia. A. HPs had a significantly shorter mean OS (9.83 months; 95%, CI 8.44-11.22) than PPs (19.18 months; 95%, CI 14.13-24.22) (log-rank test p=0.001), Ps (17.32 months; 95%, CI 15.67-18.98) (log-rank test p<0.001) and NPs (29.79 months; 95%, CI 26.87-32.71) (log-rank test p<0.001). B. Patients with ∆PMMA≥10% had a significantly shorter mean OS (13.5 months; 95%, CI 11.7-15.2) than patients with ∆PMMA<10% (31.5 months; 95%, CI 27.6-35.8) (log-rank test p<0.001).